An experimental PET scan was used to detect elevated levels of abnormal tau protein in regions of the brain affected by CTE in living former NFL players.
Researchers have developed a personalized neurological footprint, which uses a link between brain physiology, genetic profile and response to therapeutics, to predict the effectiveness of aiming treatment at various targets within individual patients.
The impact of β-amyloid positron emission tomography on the diagnostic and treatment decisions of dementia experts
Amyloid positron emission tomography (aPET) measurement of Alzheimer’s disease (AD) pathology could improve the accurate diagnosis of cognitive disorders.
In a proof-of-concept study, researchers have demonstrated that an experimental PET tracer could be used to effectively diagnose concussion-related CTE in living patients.
Recent research using a novel tau ligand demonstrates that amyloid interacts with hippocampal and cortical tau to induce neurodegeneration. Tau imaging offers the opportunity to stage Alzheimer’s disease preclinically.